SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma shines on receiving approval to raise $350 million through QIP issue

12 Dec 2014 Evaluate

Aurobindo Pharma is currently trading at Rs. 1165.00, up by 41.85 points or 3.73% from its previous closing of Rs. 1123.15 on the BSE.

The scrip opened at Rs. 1128.00 and has touched a high and low of Rs. 1166.00 and Rs. 1128.00 respectively. So far 53,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1171.20 on 09-Dec-2014 and a 52 week low of Rs. 295.50 on 13-Dec-2013.

Last one week high and low of the scrip stood at Rs. 1171.20 and Rs. 1108.00 respectively. The current market cap of the company is Rs. 33,973.00 crore.

The promoters holding in the company stood at 54.10%, while Institutions and Non-Institutions held 35.67% and 10.22% respectively.

Aurobindo Pharma has received approval for the issue of equity shares through qualified institutions placement up to $350 million. The board at its meeting held on December 10, 2014 has approved for the same. At the aforesaid meeting, it has also been decided to hold a general meeting of the members of the Company for the above purpose on January 21, 2015.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

 

Aurobindo Pharma Share Price

1380.20 -5.45 (-0.39%)
20-Apr-2026 09:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.80
Dr. Reddys Lab 1236.95
Cipla 1237.00
Zydus Lifesciences 940.75
Lupin 2338.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×